Omeros (OMER) Stock Price, News & Analysis

Company Overview

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery. Omidria is marketed in the United States through a partnership with Mallinckrodt Pharmaceuticals, with additional regulatory filings underway in selected international markets. The approval and commercialization of Omidria marked the company’s transition from a pure-research organization to a commercial stage biopharma company.

The company’s lead clinical candidate, narsoplimab (OMS721), is a human monoclonal antibody that inhibits mannan-binding lectin-associated serine protease-2 (MASP-2), a key enzyme in the lectin pathway of complement activation. Narsoplimab is being evaluated in rare, life-threatening disorders such as hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA) and IgA nephropathy. In addition, Omeros has several small-molecule programs in development, including P2X7 receptor antagonists for neuropathic pain and addiction and selective kappa opioid receptor modulators for mood disorders.

Headquartered in Seattle, Washington, Omeros was founded in 1994 and completed its initial public offering in 2010. Under the leadership of founder and CEO Gregory A. Demopulos, M.D., the company has grown to include research and development facilities in both the United States and Europe, supporting global clinical trials and regulatory activities. Omeros continues to expand its pipeline through in-house discovery efforts and strategic collaborations aimed at bringing novel therapies to patients worldwide.

Key Stats

• Today's Range: $10.95 to $12.02
• 50-Day Range: $9.81 to $14.83
• 52-Week Range: $2.95 to $17.65
• Volume: 1.83 million shs
• Average Volume: 1.44 million shs
• Market Capitalization: $797.21 million
• P/E Ratio: 15.74
• Dividend Yield: N/A
• Price Target: $40.33
• Consensus Rating: Buy

Omeros Stock Analysis - MarketRank™

Omeros scored higher than 60% of companies evaluated by MarketBeat, and ranked 181st out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Omeros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Omeros has a consensus price target of $40.33, representing about 262.4% upside from its current price of $11.13.

Amount of Analyst Coverage

Omeros has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Omeros is 16.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omeros is 16.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.85.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.12% of the float of Omeros has been sold short.

Short Interest Ratio / Days to Cover

Omeros has a short interest ratio ("days to cover") of 13.09, which indicates bearish sentiment.

Change versus previous month

Short interest in Omeros has recently decreased by 6.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omeros does not currently pay a dividend.

Dividend Growth

Omeros does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Omeros this week, compared to 4 articles on an average week.

Search Interest

Only 12 people have searched for OMER on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

MarketBeat Follows

7 people have added Omeros to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Omeros insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.90% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 5/27/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OMER
• CIK: 1285819
• Web: www.omeros.com
• Phone: (206) 676-5000
• Fax: 206-676-5005
• Employees: 210
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Omeros: $40.33
• High Price Target: $45.00
• Low Price Target: $36.00
• Potential Upside/Downside: +266.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.70
• Trailing P/E Ratio: 15.67
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.35 million
• Net Margins: N/A
• Pretax Margin: 870.06%
• Return on Equity: -102.16%
• Return on Assets: 64.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.03
• Quick Ratio: 3.03

Sales & Book Value

• Annual Sales: $9.89 million
• Price / Sales: 80.61
• Cash Flow: $1.80 per share
• Price / Cash Flow: 6.12
• Book Value: ($0.88) per share
• Price / Book: -12.52

Miscellaneous

• Outstanding Shares: 72,375,000
• Free Float: 63,039,000
• Market Cap: $797.50 million
• Optionable: Optionable
• Beta: 2.66